Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹14,892Cr
Rev Gr TTM
Revenue Growth TTM
23.46%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

EIDPARRY
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 21.1 | -1.7 | -20.0 | -21.6 | -19.0 | -4.0 | 3.0 | 12.2 | 22.6 | 29.3 | 24.6 | 18.3 |
| 6,217 | 6,359 | 8,002 | 7,349 | 5,088 | 6,263 | 8,359 | 8,018 | 6,281 | 7,918 | 10,427 | 9,481 |
Operating Profit Operating ProfitCr |
| 9.4 | 9.5 | 11.7 | 5.4 | 8.4 | 7.2 | 10.4 | 8.1 | 7.8 | 9.2 | 10.3 | 8.1 |
Other Income Other IncomeCr | -23 | -15 | 147 | 32 | 113 | 45 | 56 | 109 | 443 | 90 | 151 | 60 |
Interest Expense Interest ExpenseCr | 87 | 82 | 74 | 53 | 86 | 84 | 94 | 99 | 96 | 104 | 129 | 103 |
Depreciation DepreciationCr | 105 | 94 | 101 | 112 | 113 | 117 | 123 | 130 | 142 | 176 | 158 | 204 |
| 428 | 477 | 1,029 | 288 | 382 | 327 | 811 | 582 | 735 | 615 | 1,062 | 588 |
| 141 | 152 | 247 | 71 | 88 | 102 | 219 | 166 | 195 | 151 | 296 | 151 |
|
Growth YoY PAT Growth YoY% | -33.1 | -34.3 | 38.4 | -55.0 | 2.6 | -30.5 | -24.3 | 91.9 | 83.3 | 105.6 | 29.5 | 5.2 |
| 4.2 | 4.6 | 8.6 | 2.8 | 5.3 | 3.4 | 6.3 | 4.8 | 7.9 | 5.3 | 6.6 | 4.2 |
| 10.1 | 6.1 | 25.5 | 6.7 | 12.4 | 5.1 | 17.2 | 11.0 | 16.1 | 13.8 | 23.9 | 13.1 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 10.1 | -6.3 | 6.8 | 7.7 | 3.5 | 8.3 | 26.8 | 49.8 | -16.5 | 7.5 | 18.6 |
| 12,941 | 14,517 | 12,965 | 14,068 | 15,110 | 15,241 | 16,467 | 21,146 | 32,050 | 26,798 | 28,921 | 34,107 |
Operating Profit Operating ProfitCr |
| 7.3 | 5.5 | 9.9 | 8.5 | 8.7 | 11.0 | 11.3 | 10.1 | 9.1 | 8.9 | 8.5 | 9.0 |
Other Income Other IncomeCr | 108 | 179 | 159 | 150 | 89 | 128 | 17 | 240 | 45 | 276 | 652 | 743 |
Interest Expense Interest ExpenseCr | 420 | 451 | 417 | 336 | 425 | 430 | 236 | 152 | 298 | 295 | 372 | 432 |
Depreciation DepreciationCr | 244 | 250 | 248 | 251 | 272 | 319 | 332 | 334 | 376 | 421 | 512 | 679 |
| 455 | 319 | 920 | 868 | 837 | 1,266 | 1,539 | 2,129 | 2,564 | 2,175 | 2,455 | 3,000 |
| 179 | 144 | 211 | 351 | 399 | 377 | 540 | 555 | 737 | 558 | 682 | 793 |
|
| | -36.6 | 304.2 | -26.9 | -15.4 | 103.1 | 12.5 | 57.4 | 16.1 | -11.5 | 9.6 | 24.5 |
| 2.0 | 1.1 | 4.9 | 3.4 | 2.6 | 5.2 | 5.4 | 6.7 | 5.2 | 5.5 | 5.6 | 5.9 |
| 6.6 | 1.9 | 29.4 | 14.5 | 8.7 | 26.4 | 25.3 | 51.2 | 53.4 | 50.7 | 49.5 | 66.9 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 | 18 |
| 2,209 | 2,370 | 2,733 | 2,952 | 3,110 | 3,502 | 4,565 | 5,308 | 6,067 | 7,055 | 7,938 | 8,628 |
Current Liabilities Current LiabilitiesCr | 8,377 | 9,477 | 8,516 | 9,790 | 10,912 | 8,590 | 5,745 | 7,108 | 8,471 | 9,300 | 10,395 | 14,196 |
Non Current Liabilities Non Current LiabilitiesCr | 1,399 | 1,262 | 1,028 | 572 | 625 | 1,208 | 690 | 735 | 769 | 981 | 1,055 | 1,265 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 8,738 | 9,950 | 9,460 | 10,672 | 12,003 | 10,448 | 8,873 | 10,839 | 12,593 | 15,187 | 16,319 | 19,904 |
Non Current Assets Non Current AssetsCr | 4,161 | 4,216 | 3,972 | 3,927 | 3,987 | 4,576 | 4,390 | 5,103 | 6,185 | 6,306 | 8,063 | 10,055 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 222 | 437 | 1,969 | 259 | -52 | 1,986 | 4,771 | 2,278 | 359 | 1,974 | 1,936 |
Investing Cash Flow Investing Cash FlowCr | -307 | -190 | -148 | 13 | -358 | -292 | -560 | -1,733 | 486 | -1,740 | -2,782 |
Financing Cash Flow Financing Cash FlowCr | -142 | -221 | -1,842 | 42 | 34 | -1,769 | -3,598 | -499 | -184 | -497 | 74 |
|
Free Cash Flow Free Cash FlowCr | 35 | 233 | 1,839 | 82 | -396 | 1,628 | 4,455 | 1,845 | -370 | 1,051 | 1,323 |
| 80.2 | 249.4 | 278.0 | 50.1 | -12.0 | 223.4 | 477.2 | 144.8 | 19.6 | 122.0 | 109.2 |
CFO To EBITDA CFO To EBITDA% | 21.9 | 52.0 | 138.1 | 19.9 | -3.6 | 105.2 | 228.3 | 95.9 | 11.2 | 75.5 | 72.1 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 3,093 | 3,834 | 4,986 | 4,893 | 3,643 | 2,474 | 5,644 | 8,018 | 8,296 | 9,686 | 13,962 |
Price To Earnings Price To Earnings | 30.7 | 111.3 | 9.6 | 19.1 | 23.7 | 5.3 | 12.6 | 8.8 | 8.8 | 10.8 | 15.9 |
Price To Sales Price To Sales | 0.2 | 0.3 | 0.3 | 0.3 | 0.2 | 0.1 | 0.3 | 0.3 | 0.2 | 0.3 | 0.4 |
Price To Book Price To Book | 1.4 | 1.6 | 1.8 | 1.6 | 1.2 | 0.7 | 1.2 | 1.5 | 1.4 | 1.4 | 1.8 |
| 7.0 | 9.7 | 5.9 | 6.3 | 5.7 | 3.5 | 2.9 | 3.1 | 2.6 | 3.2 | 4.8 |
Profitability Ratios Profitability Ratios |
| 25.0 | 23.0 | 28.7 | 27.3 | 27.8 | 29.0 | 28.7 | 25.1 | 20.8 | 23.0 | 23.2 |
| 7.3 | 5.5 | 9.9 | 8.5 | 8.7 | 11.0 | 11.3 | 10.1 | 9.1 | 8.9 | 8.5 |
| 2.0 | 1.1 | 4.9 | 3.4 | 2.6 | 5.2 | 5.4 | 6.7 | 5.2 | 5.5 | 5.6 |
| 13.2 | 11.0 | 20.8 | 17.2 | 15.7 | 21.9 | 30.5 | 34.6 | 37.2 | 28.0 | 26.5 |
| 12.4 | 7.3 | 25.8 | 17.4 | 14.0 | 25.3 | 21.8 | 29.6 | 30.0 | 22.9 | 22.3 |
| 2.1 | 1.2 | 5.3 | 3.5 | 2.7 | 5.9 | 7.5 | 9.9 | 9.7 | 7.5 | 7.3 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Executive Summary**
EID Parry (India) Ltd, a member of the Murugappa Group, is undergoing a strategic transformation from a traditional sugar-focused manufacturer into a diversified **Food, Nutrition, and Bioenergy enterprise**. With a 235-year legacy and operations rooted in South India, the company is leveraging its trusted **Parry’s brand**, integrated manufacturing infrastructure, and deep agrarian engagement to expand into high-growth FMCG segments, particularly **value-added sweeteners, staples (rice, dals, millets)**, and globally competitive **nutraceuticals**. This pivot is designed to reduce vulnerability to commodity sugar cycles, regulatory risks, and climate volatility while capturing a larger share of Indian households’ grocery baskets through branded, healthy, and convenient food offerings.
---
### **Core Business Segments & Strategic Shift**
#### **1. Sugar & Bioenergy (Established Verticals)**
Despite diversification, sugar remains the core revenue generator, supported by integrated bioenergy operations:
- **Sugar Operations**
- Operates **six sugar factories** across Tamil Nadu, Andhra Pradesh, and Karnataka with a combined **cane crushing capacity of 40,800 TCD**.
- Market leader in **packaged sugar in South India** under the ‘Parrys’ brand.
- Supplies **pharma-grade, bulk, and B2B sugar** to global F&B, pharmaceutical, and confectionery companies (e.g., Coca-Cola, Dr. Reddy’s).
- Over 60% of sugar sales now come from **branded retail and institutional channels**, reducing reliance on open-market prices.
- **Bioenergy & Distillery**
- **Ethanol production capacity: 582 KLPD**, among the highest in South India.
- Strategically expanding under the **Ethanol Blending Programme (EBP)** with new plants in Haliyal (120 KLPD) and Nellikuppam (45 KLPD).
- Capable of **multi-feed distillation**—using molasses, juice, or grain—offering flexibility during supply fluctuations.
- Generates **140 MW of surplus green power** via bagasse co-generation, contributing to energy self-sufficiency and carbon neutrality goals.
---
#### **2. Consumer Product Group (CPG) – Growth Engine**
Launched in FY2023–24 (rebranded as “Parry 2.0”), the CPG represents a **strategic pivot toward FMCG** and consumer-centric innovation.
- **Product Portfolio**
- **Sweeteners**: Parry’s Amrit Gold, Amrit Brown Sugar, Jaggery, and SweetCare Low-GI Sugar (GI < 55).
- **Staples**: 15+ rice varieties, 5 millets, and 4 dals under **Parry’s Consumer Products**, targeting healthy and urban lifestyles.
- **Total SKUs**: Over **55 SKUs** across sweeteners, rice, dals, and millets.
- **Market Performance (as of Aug 2025)**
- **Non-Sweetener Sales**: Achieved **8,569 MT in Q1 FY26**, a **40% YoY volume increase** (up from 6,140 MT in Q1 FY25).
- **Non-Sweetener Revenue**: Reached **INR 291 crore in first-year sales** (FY24–25), validating early market traction.
- **Volume Growth in Staples**: H1 FY25 sales reached **82,240 MT**, up **21% YoY**, with realization improving to **₹40.19/kg**.
- **Growth Strategy**
- **Asset-light model**: Outsourcing production and co-packing to scale rapidly with low capital intensity.
- **Distribution**: Over **200,000 retail outlets** in South India (doubled from 110,000 in FY23). Target: **500,000 across India**.
- **Channels**: Kirana stores, modern trade, e-commerce, and HORECA expansion in metro and Tier 1/2 cities.
- **Marketing**: 360-degree campaigns using TV, digital, influencers, and celebrity endorsements for brand visibility.
---
#### **3. Nutraceuticals – Global Premium Segment**
A high-margin, export-oriented business with leadership in organic microalgae-based wellness.
- **Key Offerings**:
- **Organic Spirulina**: Globally recognized as premium, high-phycocyanin (>17%) product.
- **Organic Chlorella**: High chlorophyll (2–2.5%), scientifically validated for B12 bioavailability.
- **Saw Palmetto Extracts (Flomentum®)**: USP-verified B2C brand for prostate health, distributed in the USA via wholly-owned subsidiary **US Nutraceuticals Inc. (Valensa)**.
- **Manufacturing & Innovation**
- Plants in **Oonaiyur (TN)** and **Chile** (Haematococcus for Astaxanthin).
- **No sterilization policy** preserves nutrients; uses **zero/minimal excipients** in formulations.
- Engaged in clinical research: dermatology applications for Saw Palmetto, B12 absorption in Chlorella.
- **Global Presence**
- Strong in **North America, EU, and Japan**, with products meeting **USP, FSSC 22000, Bonsucro, Organic (NOP, EU), and SMETA** standards.
- Aims to reclaim leadership in **European dietary supplements**, differentiating on **quality and scientific validation** vs. low-cost Chinese alternatives.
---
### **Strategic Initiatives & Capabilities**
#### **1. Diversification & Revenue Resilience**
- **Revenue mix shift**: Non-sugar revenue (CPG, ethanol, nutraceuticals, co-gen) now a growing contributor.
- CPG revenue surged to **₹883.89 crore in FY24** from ₹535.26 crore, while sugar revenue declined.
- Goal: Reduce direct exposure to **commodity sugar markets to <10%** of total revenue.
#### **2. R&D & Innovation**
- **Cane R&D**: India’s only private sugar company with **in-house sugarcane breeding program**. Over **12 high-yield, disease-resistant** varieties developed via tissue culture.
- **New Product Development**:
- **Nucane™ Technology** (with Nutrition Innovation, Singapore): Naturally low-GI sugar using cane polyphenols.
- **Ready-to-cook health mixes**, millet idly/dosa batters, and fortified staples in pipeline.
#### **3. Sustainability & Circular Economy**
- **Zero Liquid Discharge (ZLD)**: Nellikuppam distillery operates with 100% ZLD.
- **Waste-to-Value**:
- **Green Grow Media (GGM)**: Soil-less grow medium from **bagasse**, export-ready, with 400% 30-year volume growth potential.
- **Bioplastics**: Under development—mulching sheets, poly bags from bagasse.
- **Mineralised salt licks and cattle fodder blocks** from waste.
#### **4. Digital & Precision Agriculture**
- **i-Cane Management System (iCMS)**: Mobile app for real-time farm monitoring, yield mapping, and irrigation control.
- **Autonomous irrigation, drone spraying, GPS yield tracking**, and AI-backed harvest scheduling improve efficiency and recovery rates.
- Farmer engagement with **100,000+ sugarcane farmers** across 200,000 acres; payments within **7–12 days** of delivery.
---
### **Subsidiaries & Group Synergies**
- **Coromandel International Ltd**: Farm inputs business (fertilizers, biopesticides like Azadirachtin).
- **Parry Sugars Refinery India Pvt Ltd**: World-class refinery at Kakinada, exporting containerized sugar.
- **US Nutraceuticals Inc. (Valensa)**: Fully owned US subsidiary, key to global nutraceutical growth.
- **Algavista Greentech Pvt Ltd (JV)**: Developed **Phycocyanin** (natural blue colorant), though pricing pressures from China have challenged commercial viability.
---
### **Key Risks & Mitigation**
| **Risk** | **Mitigation Strategy** |
|--------|------------------------|
| Sugar price volatility & policy changes | Diversify into higher-margin, non-regulated businesses |
| Climate & monsoon dependency | Precision farming, drought-resistant cane varieties, regional crop diversification |
| Supply chain for staples | 55 SKUs sourced from 13 suppliers across 6 states; multi-sourcing strategy |
| Nutraceutical pricing pressure (esp. from China) | Focus on quality, scientific validation, and premium positioning |
---